MOTs-C vs Epitalon: two longevity peptides, two evidence standards

The longevity menu has two compounds you almost never see on the same forum thread. MOTs-C shows up where the conversation is mitochondria, AMPK, and exercise mimetic. Epitalon shows up where the conversation is telomeres, the Khavinson group, and Russian gerontology. Different vocabularies, different reference papers, different fan bases.

They are about to share a calendar week. The same April 2026 Federal Register notice put both peptides on the FDA’s July 2026 Pharmacy Compounding Advisory Committee docket, on consecutive days, in completely unrelated indication baskets. MOTs-C is up on July 23 for obesity and osteoporosis. Epitalon is up on July 24 for insomnia. Neither indication is longevity. Both compounds are sold as longevity peptides anyway.

That parallel — same regulatory wave, opposite ends of the published evidence universe — is the cleanest frame the longevity cluster has produced so far. The article is about what the two compounds are actually carrying when you stop using the marketing category as a flattener.

A naming note before we go further

You will see Epitalon spelled both ways in the wild — Epitalon (the FDA spelling, used here) and Epithalon (most supplement and longevity marketing). Same compound. Sometimes also written as AEDG, the single-letter shorthand for the four-residue sequence Ala-Glu-Asp-Gly. MOTs-C is sometimes written MOTS-c — same compound, capitalisation drift from the mouthful of the full name, Mitochondrial Open Reading Frame of the 12S rRNA-c.

What each one is, structurally

These are not structurally similar molecules. The longevity category papers over the difference; the chemistry does not.

MOTs-C is a 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA gene — a region of the mitochondrial genome that the textbook used to say coded for almost nothing beyond the electron-transport machinery. The 2015 Cell Metabolism paper by Lee and colleagues was the discovery: MOTs-C was the first formally characterised mitochondrial-derived peptide, a small peptide written into mitochondrial DNA, translated in the mitochondrion, exported into the bloodstream, acting on metabolism systemically. The proposed mechanism is metabolic: activate AMPK, increase glucose uptake in skeletal muscle, improve insulin sensitivity, modulate fatty-acid handling. The longevity pitch hangs off that metabolic mechanism.

Epitalon is four amino acids. The shortest peptide on the longevity menu. Ala-Glu-Asp-Gly, derived from epithalamin — a bovine pineal-gland extract characterised in the 1980s by Vladimir Khavinson’s group at the St Petersburg Institute of Bioregulation and Gerontology, the same group that has run most of the published epitalon research for four decades since. The proposed mechanism is telomere-biology: induce telomerase activity, lengthen telomeres in somatic cells, modulate the aging immune response. The longevity pitch hangs off the telomere mechanism.

So already, before any clinical data: 16 amino acids versus 4. Mitochondrial-encoded versus pineal-derived. AMPK and metabolism versus telomerase and telomere length. Two unrelated mechanism stories, both routed through the supplement market as longevity peptides.

The spec sheet

Pull the basic structural and regulatory facts into one frame, because the marketing flattens them and the regulatory chart does not.

Read the spec sheet honestly. The bottom rows agree on one thing — neither compound has an FDA approval (no NDA, no BLA), and both are on the same July 2026 PCAC wave. The rows above them agree on nothing. Two unrelated structural classes, two unrelated mechanism stories, two different evidence traditions, and a PCAC reviewer assessing them for two unrelated indications. The longevity peptide label hides all of that.

The two evidence standards, side-by-side

Here is the central comparison. The headline calls it two evidence standards because that is exactly what the published literature shows once you stop reading by category and start reading by tradition.

MOTs-C’s evidence base is Western peer-reviewed, journal-quality high. The 2015 discovery paper from Lee and colleagues in Cell Metabolism is one of the most-cited papers in the mitochondrial-derived peptide literature. The 2021 follow-up by Reynolds and colleagues in Nature Communications pushed the mechanism into aging biology — aged mice given MOTs-C recovered grip strength and treadmill capacity, and the peptide moved into the nucleus under metabolic stress to regulate adaptive gene programmes. A 2022 review in the International Journal of Molecular Sciences by Mohtashami and colleagues collected the human observational picture: circulating MOTs-C levels decline with age and run lower in people with metabolic dysfunction. That is the entire shape — flagship discovery, mechanism follow-up, human association studies.

Epitalon’s evidence base is Russian peer-reviewed, with a four-decade continuous publication record from one institution. The 2001 paper from Anisimov and colleagues in Ross Fiziol Zh reported that the pineal peptide (epitalon) influenced biological-age parameters and lifespan in mice — the foundational Russian animal lifespan study underlying the anti-aging case. Russian-language publication. The 2003 paper from Khavinson and colleagues in Bull Exp Biol Med added cultured human somatic cells exposed to epitalon, with telomerase induction and telomere elongation observed. That cell-culture mechanism paper is the spine of the telomere-biology marketing. The 2015 Belgian analytical paper from Vanhee and colleagues in Drug Test Anal identified epitalon in two illegal pharmaceutical preparations seized in the European Union — useful for confirming off-label circulation, not for efficacy. The 2026 Frontiers in Aging review by Mavrych and colleagues places epitalon in the broader unapproved-peptide cluster and flags significant gaps around dosing, combination therapy, and validated biomarkers.

Two evidence bases. Both peer-reviewed. Both with a real mechanism story in cells or animals. The MOTs-C side runs through Cell Metabolism and Nature Communications and has been picked up by multiple labs working on the broader mitochondrial-derived peptide class. The Epitalon side runs almost exclusively through one Russian research tradition for four decades, with limited independent Western replication. The same paper structure on the page — peer-reviewed, mechanism shown — sits on two different reproducibility floors.

Neither side has produced what would actually move the longevity claim forward: a controlled human trial in healthy or aging adults with a functional endpoint and a placebo arm. The shape of the gap differs. For MOTs-C: the mechanism shows up clean in mice, the human story is association only, no interventional trial has been run. For Epitalon: the mechanism shows up in cultured cells from a single research lineage, the in vivo evidence is animal lifespan from one research tradition, no Western controlled human trial has been run. The headline question — which one works for longevity — has the same honest answer in both columns. Nobody has run the trial that would tell you.

The human file, side-by-side

This is where the asymmetry sharpens.

The interesting cell is the last one. Both compounds are about to be assessed by the FDA, in the same week, for indications that have almost nothing to do with the longevity marketing each is sold under. MOTs-C is being evaluated for obesity and osteoporosis, which at least overlaps with the metabolic-mechanism story. Epitalon is being evaluated for insomnia, which has no clean line to the telomere-biology pitch at all. Whatever the FDA decides in July, the longevity claims sold in the supplement market are not what the regulator is being asked to consider.

That detail keeps getting flattened in coverage. The PCAC review is not a referendum on whether MOTs-C extends life or whether Epitalon turns on telomerase in adult humans. It is a Section 503A compounding-pathway evaluation for specific FDA-reviewed indications: metabolic disease and bone density on one day, sleep on the next.

What the FDA is actually reviewing, day by day

The April 2026 Federal Register notice 2026-07361 names seven peptides across the two-day Pharmacy Compounding Advisory Committee meeting. MOTs-C and Epitalon land on opposite days, in opposite indication baskets.

July 23 — MOTs-C, alongside BPC-157, KPV, and TB-500. MOTs-C is on for obesity and osteoporosis. The metabolic case picks up the Lee 2015 mouse data on glucose handling and insulin sensitivity. PCAC is being asked whether US-licensed compounding pharmacies should be allowed to prepare MOTs-C for those specific indications with a prescription, under the Section 503A framework. Not whether the longevity pitch holds up. Not whether the exercise-mimetic framing translates to humans.

July 24 — Epitalon, alongside Emideltide (the delta sleeping inducing peptide, DSIP) and Semax. Epitalon is on for insomnia. Two of the three substances grouped on that day — DSIP and Epitalon — carry sleep-related mechanisms in their literature (DSIP literally named for delta sleep induction; Epitalon for its pineal-melatonin lineage). Semax sits in cerebral-ischaemia, migraine, and cognition territory rather than sleep — same day, different indication shape. The PCAC question for July 24 is whether compounded epitalon for insomnia, in free-base and acetate forms, meets the 503A criteria. Again — not whether epitalon extends human life.

Both reviews are advisory. PCAC makes a recommendation; the FDA decides via rulemaking after. On the PCAC docket is a meaningful regulatory marker. It is not a near-approval signal, and it is not a validation of the marketing claims sold in the off-label supplement market.

For competitive athletes, neither MOTs-C nor Epitalon appears by name on the 2026 WADA Prohibited List. The activity class each compound sits in maps onto a different WADA category — MOTs-C’s metabolic and exercise-capacity profile sits in the kind of substance S2 covers; Epitalon’s non-approved-peptide status with reported anti-aging activity sits in the kind of substance S0’s catch-all is written to cover. Athletes subject to testing should assume both are best treated as prohibited and confirm against the current code on the day of competition.

What the indication asymmetry actually reveals

There is a quieter point in the PCAC chart that the longevity marketing buries. The FDA’s choice of indication for each compound says something about which slice of each evidence base has enough rigour to be evaluated at all. MOTs-C goes up for obesity and osteoporosis because the mouse metabolic data — flagship Western journals, multiple labs working on the broader peptide class — is the slice with enough plausibility and indication-fit to put on the table. Epitalon goes up for insomnia because the sleep-architecture observations in the Russian-tradition literature are the slice with enough indication-specific signal. The telomere-biology longevity case, despite its longer publication history, did not make either compound’s indication shortlist.

The FDA is not validating any of the longevity marketing. The agency is asking whether each compound, in its narrowest plausible indication, qualifies for a compounding pathway. For MOTs-C that is metabolic; for Epitalon it is sleep. Whatever pings on the headlines after the July meeting, neither outcome will tell you anything about whether either compound extends human life, because that is not the question on the table.

What would actually change the longevity answer for each one

For MOTs-C the missing piece is a randomised controlled trial in middle-aged adults — the population actually buying it — with longevity-adjacent endpoints: body composition, glycaemic control, VO2max, grip strength. A human pharmacokinetic study would also be a precondition. Neither has been published. The Elhusseiny et al. 2025 heat-stress mitokine study in Medicine and Science in Sports and Exercise established the pathway moves in humans without a peptide injection — a starting point for the pathway is real in people, not a result on the peptide itself.

For Epitalon the missing piece is bigger. A controlled human trial of epitalon dosing with blood telomere length, telomerase activity in peripheral blood mononuclear cells, and a panel of established aging biomarkers (epigenetic age clocks, frailty indices, inflammatory markers) as primary endpoints. Independent Western replication of the Khavinson 2003 telomerase-induction work. A cancer-risk surveillance study of chronic telomerase induction, because telomerase is also active in many cancer cells and the chronic-induction-cancer question has not been resolved. None of those trials are scheduled, and there is no commercial sponsor obviously incentivised to fund them for a four-residue peptide with no patentable structure.

So which one, if you are choosing on the longevity case

A practical question lives inside the headline, and the answer comes out as four smaller questions with four different answers.

Which compound has the higher-quality published mechanism work? MOTs-C. Cell Metabolism and Nature Communications papers, multiple labs working on the broader mitochondrial-derived peptide class, a coherent metabolic-mechanism story with an indication-fit (obesity, metabolic syndrome) that the July 23 PCAC review actually picks up.

Which compound has the longer published research record overall? Epitalon. Four decades of continuous publication from Khavinson’s group, including a foundational Russian animal lifespan study and a cell-culture telomerase paper that the entire telomere-biology longevity marketing leans on. The record is long and consistent; the reproducibility floor is what it is.

Which compound has actually been tested in humans for what people are buying it for? Neither. The Elhusseiny et al. 2025 heat-stress study moved a biomarker; nobody got injected with MOTs-C. The Russian observational reports on epitalon describe off-label use but do not constitute a controlled trial. Both peptides are sold for longevity, and neither has a controlled human trial supporting that case.

Which compound’s FDA review actually maps onto its marketing? The closer fit is MOTs-C — obesity overlaps with the metabolic-mechanism pitch, even though the longevity claim itself is downstream. The Epitalon review is for insomnia, which has essentially no overlap with the telomere-biology pitch the supplement market runs.

A favourable PCAC recommendation followed by favourable FDA rulemaking would put either compound on a regulatory footing for compounded prescribing for the named indication. It would not validate the longevity claim on either side, because that claim is not what the agency is evaluating.

Two evidence standards, one regulatory week — what that combination actually settles

Two peptides sold under the same longevity label, sitting on two different reproducibility floors, with their regulatory reviews scheduled for consecutive days in unrelated indication baskets. MOTs-C carries Cell Metabolism plus Nature Communications plus a multi-lab mitochondrial-derived peptide field, and goes up on July 23 for obesity and osteoporosis. Epitalon carries four decades of Russian research from one institution, and goes up on July 24 for insomnia. The headline question — which longevity peptide is better — collapses into something smaller and harder once the evidence bases stop being treated as interchangeable. The two evidence standards do not produce one answer because they were never asking the same question.

When the legitimate version exists

Wolverine Health is being built for the moment a legitimate version of each of these compounds exists — a US-licensed compounding pharmacy preparing the molecule for a named patient, with a supervising physician’s prescription for the indication the FDA has actually evaluated, and an evidence base honestly stated alongside the pitch. For MOTs-C that indication, if the July 23 review lands favourably and rulemaking follows, will be obesity or osteoporosis — not longevity. For Epitalon that indication, if the July 24 review lands favourably and rulemaking follows, will be insomnia — not anti-aging. The longevity case stays where it is on both sides, with the same gaps it has now, until somebody runs the trials that would change it.

That is the prescribing context the Wolverine Health protocol is designed around — not the marketing claim, but what a US-licensed physician can actually sign off on once the legal floor is in place. Join the waitlist if you want a heads-up the moment that floor exists for either compound, and the candor on what the change does and does not establish.